C07D 515/10
Spiro-condensed systems
C07D515/10 (Spiro-condensed systems) appears on 18 US grants and 25 published applications in this corpus.
Search patents in C07D- Granted patents
- 18
- Published applications
- 25
- Assignees
- 17
- Inventors
- 133
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2011 | 0 | 2 |
| 2012 | 0 | 0 |
| 2013 | 1 | 2 |
| 2014 | 4 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 1 | 2 |
| 2018 | 0 | 1 |
| 2019 | 1 | 1 |
| 2020 | 2 | 2 |
| 2021 | 2 | 3 |
| 2022 | 3 | 1 |
| 2023 | 0 | 4 |
| 2024 | 2 | 1 |
| 2025 | 1 | 4 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Orexin receptor agonists and uses thereof29 Sep 2026US 12,747,252 B2Jazz Pharmaceuticals Ireland Limited
- Benzotriazole compound5 Aug 2025US 12,378,260 B2Daiichi Sankyo Company, Limited
- Compounds that inhibit MCL-1 protein17 Sep 2024US 12,091,425 B2Amgen Inc.
- Inhibitors of KEAP1-Nrf2 protein-protein interaction13 Feb 2024US 11,897,900 B2Janssen Pharmaceutica NV
- Macrocyclic spiroethers as Mcl-1 inhibitors15 Nov 2022US 11,498,928 B2Ascentage Pharma Group Corp Limited
- Substituted Bicyclic Heteroaryl Sulfonamide Derivatives for the Treatment of Cancer12 Feb 2026US 2026/0042754 A1Nodus Oncology Limited
- Covalent fluorescent probes for cannabinoid receptor 223 Oct 2025US 2025/0325711 A1Hoffmann-La Roche Inc.
- Benzotriazole compound23 Oct 2025US 2025/0326770 A1Daiichi Sankyo Company, Limited
- Benzotriazole compound11 Sep 2025US 2025/0282724 A1Daiichi Sankyo Company, Limited
- Benzotriazole compound20 Mar 2025US 2025/0092064 A1Daiichi Sankyo Company, Limited
Most cited
By later US patents
- 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors5US 9,845,301 B2Pfizer Inc. · 2017
- 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors2US 10,428,034 B2Pfizer Inc. · 2019
- Inhibitors of KEAP1-Nrf2 protein-protein interaction2US 10,947,252 B2Janssen Pharmaceutica NV · 2021
- Compounds that inhibit MCL-1 protein2US 11,306,107 B2Amgen Inc. · 2022
- Resin composition comprising a cyclic carbodiimide2US 8,592,529 B2Teijin Limited · 2013